Cannabis Use and CKD : Epidemiological Associations and Mendelian Randomization
© 2022 The Authors..
Rationale & Objective: The association between cannabis use and chronic kidney disease (CKD) is controversial. We aimed to assess association of CKD with cannabis use in a large cohort study and then assess causality using Mendelian randomization with a genome-wide association study (GWAS).
Study Design: Retrospective cohort study and genome-wide association study.
Setting & Participants: The retrospective study was conducted on the All of Us cohort (N=223,354). Genetic instruments for cannabis use disorder were identified from 3 GWAS: the Psychiatric Genomics Consortium Substance Use Disorders, iPSYCH, and deCODE (N=384,032). Association between genetic instruments and CKD was investigated in the CKDGen GWAS (N > 1.2 million).
Exposure: Cannabis consumption.
Outcomes: CKD outcomes included: cystatin-C and creatinine-based kidney function, proteinuria, and blood urea nitrogen.
Analytical Approach: We conducted association analyses to test for frequency of cannabis use and CKD. To evaluate causality, we performed a 2-sample Mendelian randomization.
Results: In the retrospective study, compared to former users, less than monthly (OR, 1.01; 95% CI, 0.87-1.18; P = 0.87) and monthly cannabis users (OR, 1.15; 95% CI, 0.86-1.52; P = 0.33) did not have higher CKD odds. Conversely, weekly (OR, 1.28; 95% CI, 1.01-1.60; P = 0.04) and daily use (OR, 1.25; 95% CI, 1.04-1.50; P = 0.02) was significantly associated with CKD, adjusted for multiple confounders. In Mendelian randomization, genetic liability to cannabis use disorder was not associated with increased odds for CKD (OR, 1.00; 95% CI, 0.99-1.01; P = 0.96). These results were robust across different Mendelian randomization techniques and multiple kidney traits.
Limitations: Likely underreporting of cannabis use. In Mendelian randomization, genetic instruments were identified in the GWAS that included individuals primarily of European ancestry.
Conclusions: Despite the epidemiological association between cannabis use and CKD, there was no evidence of a causal effect, indicating confounding in observational studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Kidney medicine - 5(2023), 2 vom: 19. Feb., Seite 100582 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dellepiane, Sergio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cannabis |
|---|
| Anmerkungen: |
Date Revised 19.04.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.xkme.2022.100582 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352227206 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352227206 | ||
| 003 | DE-627 | ||
| 005 | 20231226053233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xkme.2022.100582 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352227206 | ||
| 035 | |a (NLM)36712313 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dellepiane, Sergio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cannabis Use and CKD |b Epidemiological Associations and Mendelian Randomization |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.04.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. | ||
| 520 | |a Rationale & Objective: The association between cannabis use and chronic kidney disease (CKD) is controversial. We aimed to assess association of CKD with cannabis use in a large cohort study and then assess causality using Mendelian randomization with a genome-wide association study (GWAS) | ||
| 520 | |a Study Design: Retrospective cohort study and genome-wide association study | ||
| 520 | |a Setting & Participants: The retrospective study was conducted on the All of Us cohort (N=223,354). Genetic instruments for cannabis use disorder were identified from 3 GWAS: the Psychiatric Genomics Consortium Substance Use Disorders, iPSYCH, and deCODE (N=384,032). Association between genetic instruments and CKD was investigated in the CKDGen GWAS (N > 1.2 million) | ||
| 520 | |a Exposure: Cannabis consumption | ||
| 520 | |a Outcomes: CKD outcomes included: cystatin-C and creatinine-based kidney function, proteinuria, and blood urea nitrogen | ||
| 520 | |a Analytical Approach: We conducted association analyses to test for frequency of cannabis use and CKD. To evaluate causality, we performed a 2-sample Mendelian randomization | ||
| 520 | |a Results: In the retrospective study, compared to former users, less than monthly (OR, 1.01; 95% CI, 0.87-1.18; P = 0.87) and monthly cannabis users (OR, 1.15; 95% CI, 0.86-1.52; P = 0.33) did not have higher CKD odds. Conversely, weekly (OR, 1.28; 95% CI, 1.01-1.60; P = 0.04) and daily use (OR, 1.25; 95% CI, 1.04-1.50; P = 0.02) was significantly associated with CKD, adjusted for multiple confounders. In Mendelian randomization, genetic liability to cannabis use disorder was not associated with increased odds for CKD (OR, 1.00; 95% CI, 0.99-1.01; P = 0.96). These results were robust across different Mendelian randomization techniques and multiple kidney traits | ||
| 520 | |a Limitations: Likely underreporting of cannabis use. In Mendelian randomization, genetic instruments were identified in the GWAS that included individuals primarily of European ancestry | ||
| 520 | |a Conclusions: Despite the epidemiological association between cannabis use and CKD, there was no evidence of a causal effect, indicating confounding in observational studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cannabis | |
| 650 | 4 | |a Mendelian randomization | |
| 650 | 4 | |a chronic kidney disease | |
| 700 | 1 | |a Paranjpe, Ishan |e verfasserin |4 aut | |
| 700 | 1 | |a Rajagopal, Madhumitha |e verfasserin |4 aut | |
| 700 | 1 | |a Kamat, Samir |e verfasserin |4 aut | |
| 700 | 1 | |a O'Hagan, Ross |e verfasserin |4 aut | |
| 700 | 1 | |a Gulamali, Faris |e verfasserin |4 aut | |
| 700 | 1 | |a Rein, Joshua L |e verfasserin |4 aut | |
| 700 | 1 | |a Charney, Alexander W |e verfasserin |4 aut | |
| 700 | 1 | |a Do, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Coca, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Glicksberg, Benjamin S |e verfasserin |4 aut | |
| 700 | 1 | |a Nadkarni, Girish N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney medicine |d 2019 |g 5(2023), 2 vom: 19. Feb., Seite 100582 |w (DE-627)NLM303572787 |x 2590-0595 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2023 |g number:2 |g day:19 |g month:02 |g pages:100582 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xkme.2022.100582 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2023 |e 2 |b 19 |c 02 |h 100582 | ||